Curative Biotechnology, Inc. develops biomedical therapies with a current focus on degenerative eye diseases. Company news centers on its metformin-based topical ophthalmic formulation, a program supported by a worldwide exclusive license from the National Eye Institute at the NIH and a Cooperative Research and Development Agreement with the NEI. Updates also cover research agreements, clinical-supply manufacturing for sterile ophthalmic drops, and translational work spanning age-related macular degeneration and veterinary retinal degeneration models.
Recurring corporate developments include capital-structure actions such as the completed reverse stock split, strategic and financial advisory engagements, board and clinical-development governance updates, and material agreements tied to the company’s ophthalmology platform.
Curative Biotechnology (OTC: CUBT) announced a trading symbol change from CTYX to CUBT and a corporate name change to better reflect its mission in rare disease therapeutics. Chairman Paul Michaels emphasized the transformation in mission and leadership with the addition of renowned scientists Dr. Kapil Bharti and Dr. Dimiter Dimitrov to the Scientific and Clinical Advisory Board. Bharti is noted for developing treatments for eye diseases, while Dimitrov focuses on antibody therapeutics. Curative plans to file an IND for a metformin reformulation to treat wet AMD.
Curative Biotechnology, Inc. (OTC: CUBT) announced a trading symbol change from CTYX to CUBT as part of its rebranding efforts. This name change reflects the company's mission to develop novel therapies for rare diseases. The company also appointed two experts to its Scientific and Clinical Advisory Board: Dr. Kapil Bharti and Dr. Dimiter Dimitrov, who will guide pre-clinical and clinical trials. Additionally, Curative plans to file an Investigational New Drug Application for a reformulated metformin treatment for wet Age-related Macular Degeneration by year-end.